The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity.
Islet amyloid polypeptide (IAPP, amylin) is the major protein component of the islet amyloid deposits associated with type 2 diabetes. The polypeptide lacks a well-defined structure in its monomeric state but readily assembles to form amyloid. Amyloid fibrils formed from IAPP, intermediates generated in the assembly of IAPP amyloid, or both are toxic to β-cells, suggesting that islet amyloid formation may contribute to the pathology of type 2 diabetes. There are relatively few reported inhibitors of amyloid formation by IAPP. Here we show that the tea-derived flavanol, (-)-epigallocatechin 3-gallate [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate] (EGCG), is an effective inhibitor of in vitro IAPP amyloid formation and disaggregates preformed amyloid fibrils derived from IAPP. The compound is thus one of a very small set of molecules which have been shown to disaggregate IAPP amyloid fibrils. Fluorescence-detected thioflavin-T binding assays and transmission electron microscopy confirm that the compound inhibits unseeded amyloid fibril formation as well as disaggregates IAPP amyloid. Seeding studies show that the complex formed by IAPP and EGCG does not seed amyloid formation by IAPP. In this regard, the behavior of IAPP is similar to the reported interactions of Aβ and α-synuclein with EGCG. Alamar blue assays and light microscopy indicate that the compound protects cultured rat INS-1 cells against IAPP-induced toxicity. Thus, EGCG offers an interesting lead structure for further development of inhibitors of IAPP amyloid formation and compounds that disaggregate IAPP amyloid.
Meng
Fanling
F
Department of Chemistry, State University of New York at Stony Brook, Stony Brook, New York 11794-3400, USA.
Abedini
Andisheh
A
Plesner
Annette
A
Verchere
C Bruce
CB
Raleigh
Daniel P
DP
D000682:Amyloid / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor; D000818:Animals; D052160:Benzothiazoles; D002392:Catechin / Q000031:analogs & derivatives; D018929:Cell Culture Techniques; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism / Q000473:pathology; D005419:Flavonoids; D058228:Islet Amyloid Polypeptide; D046529:Microscopy, Electron, Transmission; D010636:Phenols; D059808:Polyphenols; D058255:Protease Nexins; D051381:Rats; D011956:Receptors, Cell Surface; D013844:Thiazoles; D051844:alpha-Synuclein / Q000032:analysis / Q000378:metabolism
D000682:Amyloid; D016564:Amyloid beta-Protein Precursor; D052160:Benzothiazoles; D005419:Flavonoids; D058228:Islet Amyloid Polypeptide; D010636:Phenols; D059808:Polyphenols; D058255:Protease Nexins; D011956:Receptors, Cell Surface; D013844:Thiazoles; D051844:alpha-Synuclein; C009462:thioflavin T; D002392:Catechin; C045651:epigallocatechin gallate